BÜHLMANN fCAL® ELISA Citation
Lara Hart et al. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis, Journal of Crohn’s and Colitis, Volume 14, Issue 1, January 2020, DOI: doi.org/10.1093/ecco-jcc/jjz107
BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use.
Health Canada License: 80726
This citation describes applications that are outside of product claims (Intended use is: The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.) thus this “non-diagnosis” citations should be used for information only.
